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Abstract
Depression and anxiety cause severe loss of quality of life for patients with systemic lupus erythematosus. The causes and factors
that contribute to these psychological manifestations in lupus are difficult to disentangle. This study compared clinical, psychological,
and demographic factors between lupus patients, depressed patients, and rheumatoid arthritis patients to discover lupus-specific
contributors to depression. Lupus-specific manifestations of depression were also investigated.
Physiological, clinical, and psychosocial data were collected from 77 patients. ELISA was used to measure cytokine levels.
Univariate andMultivariate analyses were used to compare the patient populations and identify correlations between key physical and
psychological indicators.
The prevalence of depression in the SLE cohort was 6 times greater than the healthy control subjects. Pain, IL-6, and Pittsburgh
Sleep Quality index values were all significantly higher in SLE patients compared with the healthy control group (P< .001, P= .038,
and P= .005, respectively). Anxiety levels were significantly higher in SLE patients compared to healthy and RA control patients
(P= .020 and .011, respectively). Serum IL-10 concentrations, relationship assessment scale, and fatigue severity scale values were
found to be correlated with depression among the SLE patients (P= .036, P= .007, and P= .001, respectively). Relationship
assessment and fatigue severity scale scores were found to be the best indicators of depression for the SLE patients (P= .042 and
.028, respectively).
Fatigue Severity, relationship satisfaction, and IL-10 concentrations are indicators of depression in lupus patients. Despite also
suffering from the pain and disability that accompanies chronic autoimmune disease, the rheumatoid arthritis patients had less
anxiety and better relationship scores.
Abbreviations: CRP = C-reactive protein, EPE = Ethical Committee, ESR = erythrocyte sedimentation rate, FSS = Fatigue
Severity Scale, HADS = Hospital Anxiety and Depression Scale, IL = interleukin, PSQI = Pittsburgh Sleep Quality Index, RA =
rheumatoid arthritis, RAS = Relationship Assessment Scale, SF-36 =Medical Outcomes Study Questionnaire Short Form 36 Health
Survey, SLE = systemic lupus erythematosus, Th = T-helper, TNF = tumor necrosis factor.
Keywords: depression, IL-10, lupus, rheumatoid arthritis
1. Introduction
Systemic lupus erythematosus (SLE) is a common autoimmune
disease afflicting 1 to 12 people per 5000 worldwide.[1]
Symptoms often include fever, arthritis, fatigue, weight loss,
lymphadenopathy, a characteristic “butterfly rash,” renal disease
and cytopenia, in a pleomorphic clinical presentation. Psycho-
logical manifestations such as depression and anxiety are very
common. Major depression is present in approximately 25% of
lupus patients, and major anxiety in 37%.[2] These presentations
are often among the earliest symptoms to manifest in lupus.[3,4]
There are mixed results regarding the association between lupus
disease activity and depression and anxiety, with some studies
showing a connection and others finding no association.[5–9]
Several factors have been linked to depression in lupus, including
certain autoantibody specificities, neurological damage, presence
of rashes, and the concentration of certain cytokines. Socioeco-
nomic status, and factors associated with socioeconomic status,
such as reserve capacity and psychological resilience, affect the
relationship between depression and anxiety in lupus.[10,11] These
diverse findings indicate the depression and anxiety in lupus is
likely mediated through a complex mixture of biological, social,
economical, and environmental contributors.
Fatigue and pain are frequently rated by SLE patients as having
a strong negative effect on quality of life.[12,13] Clinical tests
attempting to measure severity of disease fail to satisfactorily
correlate with fatigue and pain in SLE patients, making it difficult
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to estimate patient discomfort and subsequently apply appropri-
ate treatments in a timely manner.[7]
SLE is associated with depression, a finding that may result
from both the physical effect of the autoimmunity on the nervous
system and the suffering due to pain and disability. Many
confounding variables exist in the lupus patient population,
including age, disease activity, weight, fatigue, sleep, and physical
activity. Therefore, it is no simple matter to identify both
psychological and physical factors that contribute to the mood
disorders in SLE patients.
Lupus is such a heterogeneous disease that even evaluating
disease activity is difficult. Lupus patients also tend to have
unexpected presentation of inflammatory markers. For example,
the C-reactive protein (CRP) levels can be lower than expected
with respect to the erythrocyte sedimentation rate (ESR)
scores.[14] Both ESR and CRP appear to behave differently
when opportunistic infection appears or in the presence of a flare,
representing a valuable clinical tool. Inflammatory markers can
give insight into clinical disease status, but need to be used in
conjunction with other tests and patient history to be effective.[15]
Very little is known about the relationship between inflammatory
markers and depression in lupus.
Rheumatoid arthritis (RA) is a highly prevalent autoimmune
disease, affecting 0.5 to 1% of the population worldwide[16] with
an important contribution to global disability.[16] In RA, immune
complexes cause local joint inflammation promoting an inflam-
matory response responsible for severe pain and fatigue.[17] This
inflammation also provokes systemic responses, including greater
risk for cardiovascular disease.[18] Rheumatoid arthritis is also
associated with psychological manifestations, although not to the
same extent as lupus. Multiple causes appear to be implicated in
RA-associated depression.[19,20] For this work, rheumatoid
arthritis patients were used as a control group to understand
what aspects of lupus-associated depression and anxiety could be
attributed to generalized pain, fatigue, and disability associated
with chronic autoimmune disease. This allows us to separate these
more general effects common to both diseases from lupus-specific
manifestations of psychological distress.
We hypothesized that depression in lupus is not merely caused
by the effects of pain and disability associated with autoimmune
disease in general, but has aspects that are specific to lupus. To
identify these lupus-specific aspects of lupus-associated depres-
sion, we compared depression in lupus patients with rheumatoid
arthritis patients and with patients with primary depression. We
further hypothesize that psychosocial factors, such as education
level and marital status, are associated with depression and
anxiety in lupus. By identifying the aspects of lupus-associated
depression that are specific to lupus, we hope to better understand
and potentially treat this quality of life-diminishing aspect of
lupus.
2. Methods
2.1. Study patients
This cohort study included 77 total Caucasian patients, 15
patients with systemic lupus erythematosus (SLE), 21 rheumatoid
arthritis (RA) patients, 20 healthy control subjects, and 21
otherwise healthy patients seeking treatment for depression
(primary depression). All patients were recruited from the same
geographic region (northern Portugal). All SLE and RA patients
were previously diagnosed according to ACR criteria and
followed at an outpatient unit. Diagnosis and stage of disease
activity was established according to the American Rheumatism
Association Classification Criteria[21] for Rheumatoid Arthritis
and the 1997 American college of Rheumatology criteria for
diagnosing SLE. The duration of the disease was measured from
the time when the patients first met at least 4 of the classification
criteria. These patients were recruited from the Rheumatology
service at the time of a clinic visit, and were being treated at the
time of the study.
The primary depression subjects were recruited from a group
of patients diagnosed with depression by a psychiatrist and
undergoing treatment at a private psychiatric clinic.
To eliminate inter-interviewer variation, psychiatric evaluation
and psychometric markers were tested by 1 psychiatrist and 1
psychologist to establish the severity of depression. A conve-
nience age-matched sample of healthy women was also recruited.
Exclusion criteria comprised history of substance abuse,
personality disorders, and/or other major psychopathology than
depression. Patients and controls were subsequently interviewed
by phone by trained interviewers using the Hospital Anxiety and
Depression Scale, as well as other psychosocial instruments
described below. The literature corroborates phone interviews as
valid and precise tools for psychological data collection.[22]
Participants’ socio-demographic data included age, education-
al level, employment status (active/nonactive), and marital status
(Table 1). Laboratory and SLE clinical evaluations were obtained
for the SLE and rheumatoid arthritis patients through the clinical
records (Table 2). Lab tests included leukocytes (109/L),
lymphocytes (percentage), platelets (109/L), erythrocyte sedimen-
tation rate (mm/h), anti-dsDNA antibody titer (IU/mL), and C-
reactive protein level (mg/dL). Serum levels of IL-6 (pg/mL), IL-
10(pg/mL, and TNF-a (pg/mL) were measured using standard-
ized ELISA assays, utilized per manufacturer’s instructions
(EBiosciences). The confounding variables of physical activity,
smoking, and alcohol consumption were also recorded. Further,
physical activity was assessed based on involvement in sporting
activities.
The study was submitted and approved by the Ethical
Committee of the São João Hospital IRB (EPE) in accordance
with the Declaration of Helsinki. The nature and the purpose of
the study were explained to all participants who signed the
informed consent form before they entered the study.
2.2. Psychosocial evaluation
Socio-demographic characterization included age, education
measured as years of school, marital status, and socio-economic
class evaluation. Psychological evaluations were obtained
through a battery of standardized instruments. The Chronbach’s
alpha for each of these scales is shown in Table 3.
2.2.1. Fatigue severity scale (FSS). The short form of the FSS
allows evaluation of self-reported fatigue.[23] The Portuguese
version includes 9 items and is recommended as the instrument of
choice for research purposes in studies involving patients
diagnosed with SLE.[24]
The FSS demonstrates good psychometric properties (Cron-
bach’s a= 0.89 and test–retest reliability 0.84). A final score is
obtained from the mean of all scored items, with higher scores
revealing higher severity of fatigue. Presence of clinical levels of
fatigue was defined by a FSS score>3. The scale has proved to be
sensitive to change and reliable for telephone interviewing. The
FSS has also been shown to be reliable across different patient
populations.[25]
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2.2.2. Hospital anxiety and depression scale (HADS). The
Hospital Anxiety and Depression Scale (HADS) is a self-rating
scale with good psychometric properties (Cronbach’s alpha
coefficients of 0.94), designed to measure anxiety and depression
in physically ill individuals.[26] Translated and adapted for
Portugal,[27] it is subdivided in2 subscales of 7 items that
independently measure anxiety and depression. The partial result
of each scale varies between 0 and 21. Scores ranging from 8 to 10
are considered mild, from 11 to 14 moderate, and 15 to 21
severe[28] and the authors suggest 8 as the cutoff point,
considering values below as indicating the absence of anxiety
and depression.[26] It is important to note that the scale is
indicative of depressive symptoms in the last week, and not
necessarily clinical depression. As such, it is a measure that
evaluates current symptoms that are commonly present during
major depressive episodes; however, it does not delineate specifics
for the diagnosis of a major depressive episode. The score can
change over time even in depressed individuals.
2.2.3. Pittsburgh sleep quality index (PSQI). This instrument
presents good psychometric properties, with high reliability
(Cronbach’s alpha=0.83) and validity. The 7 components
evaluated: sleep latency, sleep disturbances, sleep duration, sleep
quality, sleep efficiency, use of sleep medications and daytime
dysfunction allow the gathering of a global score varying from 0
to 21.[29] The PSQI is reliable for sleep quality assessment in
telephone interviews and permits the identification of poor
sleepers (score> 5).[30] A higher PSQI indicates a lower quality of
sleep whereas a higher quality of sleep is indicated by lower
scores. Normal PSQIs are reported being anywhere between 0
and 5. Any index above 5 indicates poor sleep quality for the
patient.
2.2.4. Relationship assessment scale (RAS). The RAS[31]
(Portuguese experimental version from Mesquita, Barbosa, &
Figueiredo-Braga, 2014) is a 7-item instrument, with a 5-point
scale that measures general satisfaction with the relationship.
2.2.5. Medical Outcomes Study Questionnaire Short Form
36 Health Survey (SF-36). The SF-36,[32] Portuguese version,[33]
is a 36-item questionnaire that measures functional health and
well-being in 8 domains: physical functioning, role-physical,
bodily pain, general health, vitality, social functioning, role-
emotional, mental health, and reported health transition. The
instrument allows a score for each domain, as well as a global
score. Higher scores indicate better health.
2.3. Statistical analysis
Significant differences in the demographical, clinical, and
psychological variables between the SLE subjects, healthy
controls, RA subjects, and primary depression subjects were
determined using the independent t-test, Fisher exact x2, Mann–
WhitneyU, Wilcoxon rank sum, or Welch tests when considered
appropriate. Fishers exact x2 was used in place of the standard x2
test, which would typically be utilized, due to the smaller sample
size of the groups compared. The statistical test used for the
comparisons is indicated in the table legends.
Univariate analysis was accomplished by using generalized
linear regression with HADS depression scores as the dependent
variable and the individual variable suspected of showing a
correlation to depression as the independent variable.
2.4. Multivariate analysis
Multivariate analysis was performed using a generalized linear
model on all variables examined in the study with the exception
of socioeconomic status, age, and anxiety. The best fit model was
determined using the model with the appropriate number of
variables (less than or equal to 2 variables due to the small SLE
Table 1
Sociodemographic of the study cohort.
Characteristics
All subjects
(N=77)
SLE subjects
(N=15)
Healthy subjects
(N=20) t value P value
Depressed
subjects (N=21) t value P value
RA subjects
(N=21) t value P value
Sex—no. (%) .571† .250† .062†
Female 67 (87%) 15 (100%) 19 (95%) 18 (86%) 16 (73%)
Male 10 (13%) 0 (0%) 1 (5%) 3 (14%) 5 (24%)
Age, mean±SD 48.38±12.17 49±8.21 43.95±11.77 -1.420 .165
∗
47.81±14.8 –0.281 .780
∗
52.71±11.17 1.092 .282
∗
Education Lvl (yr)±SD 9.73±4.8 7.6±3.98 13.5±3.15 4.897 <.001
∗
9.76±4.36 1.521 .138
∗
7.62±5.08 0.012 .990
∗
Education Lvl—no. (%) <.001† .264† .229†
Primary (<4 yrs) 17 (22%) 4 (27%) 0 (0%) 4 (19%) 9 (43%)
Middle school
(4 < 12 yrs)
17 (22%) 7 (47%) 1 (5%) 4 (19%) 5 (24%)
High school (12<14 yrs) 10 (13%) 1 (7%) 2 (10%) 5 (24%) 2 (10%)
College (14  18 yrs) 33 (43%) 3 (2%) 17 (85%) 8 (38%) 5 (24%)
Marital status—no. (%) .123† .495† .818†
Unmarried 17 (22%) 2 (13%) 8 (40%) 5 (24%) 2 (10%)
Married 50 (65%) 12 (80%) 8 (40%) 13 (62%) 16 (76%)
Divorced 8 (10%) 1 (7%) 4 (20%) 1 (5%) 2 (10%)
Widowed 3 (4%) 0 (0%) 0 (0%) 2 (10%) 1 (5%)
Unemployed—no. (%) .044† .175† .482†
Yes 38 (49%) 10 (67%) 6 (30%) 8 (38%) 14 (67%)
No 39 (51%) 5 (33%) 14 (70%) 13 (62%) 7 (33%)
SLE= systemic lupus erythematosus, RA= rheumatoid arthritis.
∗
Independent samples t test.
† Fisher exact x2 test.
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cohort) and the highest pseudo R2 value with the lowest
approximate AICc value. In the multivariate analysis, the HADS
depression score for the SLE subjects was used as the dependent
variable. Statistical analysis was performed using the statistical
software R and SPSS (IBM). The generalized linear model was
used because some of the independent variables used in the model
did not have normal distributions, which is typical with the data
we are working with. The parameter limits of the best fit model
were determined using the model with the appropriate number of
variables (less than or equal to 2 dependent variables due to the
small SLE cohort) and the highest pseudo R2 value (less than or
equal to 0.65) with the lowest approximate AICc value. This
model allows for more flexibility when working with the type of
distributions demonstrated by variables recorded from our
Table 3
Cronbach alpha for psychosocial assessment data sets.
SLE Healthy Depressed RA
Hospital Anxiety and Depression Scale 0.883 0.860 0.896 0.796
Pittsburgh Sleep Quality Index 0.745 0.441 0.726 0.872
Relationship Assessment Scale 0.714 0.864 0.789 0.770
Fatigue Severity Scale 0.946 0.897 0.960 0.921
Table 2
Univariate analysis of the study cohorts.
SLE subject cohort [SLE HADS depression ∼ SLE characteristic]
Characteristics Psuedo R2 AICc Coefficient Odds ratio (95% CI) P value
Disease duration (yrs), mean±SD 0.008 99.73 0.004 1.00 (0.98–1.03) .736
Body mass index, mean±SD 0.142 97.55 0.016 1.02 (1.00–1.04) .116
Pain Score, median 0.128 97.79 0.044 1.04 (0.98–1.11) .161
Sedimentation velocity (mm/h), mean±SD 0.590 88.46 0.006 1.01 (1.00–1.01) .197
C-reactive protein (mg/L), mean±SD 0.603 88.03 0.600 1.82 (0.79–4.06) .150
Leukocytes (109/L), mean±SD 0.575 88.92 0.051 0.95 (0.86–1.04) .294
Lymphocytes (%), mean±SD 0.588 88.50 0.017 0.98 (0.96–1.01) .203
Anti-dsDNA (IU/mL), mean±SD 0.549 89.70 0.000 1.00 (1.00–1.00) .565
IL-6 (pg/mL), mean±SD 0.575 88.92 0.009 0.95 (0.86–1.04) .680
IL-10 (pg/mL), mean±SD 0.463 91.22 0.057 0.94 (0.89–0.99) .036
TNF-Alpha (pg/mL), mean±SD 0.380 93.25 0.002 1.00 (1.00–1.00) .118
PSQI, mean±SD 0.056 98.97 0.028 1.03 (0.97–1.09) .352
Relationship Assessment Scale, mean±SD 0.926 68.96 0.064 0.94 (0.89–0.98) .007
Fatigue Severity Scale, mean±SD 0.565 87.35 0.273 1.31 (1.13–1.54) .001
Depressed subject cohort [depressed HADS depression ∼ depressed characteristic]
Characteristics Psuedo R2 AICc Coefficient Odds ratio (95% CI) P value
Body mass index, mean±SD 0.010 148.14 0.008 1.01 (0.97–1.04) .659
Pain Score, median 0.630 128.46 0.138 1.15 (1.08–1.22) <.001
IL-6 (pg/mL), mean±SD 0.207 143.68 0.064 1.07 (1.01–1.12) .020
IL-10 (pg/mL), mean±SD 0.325 140.48 0.014 1.01 (1.00–1.02) .003
TNF-Alpha (pg/mL), mean±SD 0.119 145.79 0.002 1.00 (1.00–1.00) .093
PSQI, mean±SD 0.249 142.60 0.051 1.05 (1.01–1.10) .018
Relationship Assessment Scale, mean±SD 0.999 45.97 0.084 0.92 (0.87–0.97) <.001
Fatigue Severity Scale, mean±SD 0.734 123.24 0.191 1.21 (1.11–1.32) <.001
RA subject cohort [RA HADS depression ∼ RA characteristic]
Characteristics Psuedo R2 AICc Coefficent Odds ratio (95% CI) P value
Disease duration (yrs), mean±SD 0.935 117.71 0.011 1.01 (0.99–1.03) .190
Body mass index, mean±SD 0.014 119.05 0.011 0.99 (0.95–1.03) .634
Pain Score, median 0.516 107.67 0.166 1.18 (1.07–1.31) .001
Sedimentation velocity (mm/h), mean±SD 0.452 109.64 0.016 1.02 (1.01–1.02) <.001
C-reactive protein (mg/L), mean±SD 0.317 113.18 0.017 1.02 (1.00–1.03) .006
Leukocytes (109/L), mean±SD 0.006 119.17 0.008 0.99 (0.94–1.04) .752
Lymphocytes (%), mean±SD 0.392 111.33 0.037 0.96 (0.94–0.99) .004
Anti-dsDNA (IU/mL), mean±SD < 0.001 119.27 0.000 1.00 (1.00–1.00) .922
IL-6 (pg/mL), mean±SD 0.988 75.51 0.006 1.01 (0.98–1.03) .597
IL-10 (pg/mL), mean±SD 0.994 68.99 0.121 1.13 (1.03–1.23) .005
TNF-Alpha (pg/mL), mean±SD 0.988 75.19 0.001 1.00 (1.00–1.00) .430
PSQI, mean±SD < 0.001 119.27 0.002 1.00 (0.96–1.04) .929
Relationship Assessment Scale, mean±SD 0.966 82.71 0.040 0.96 (0.92–1.01) .073
Fatigue Severity Scale, mean±SD 0.677 102.41 0.272 1.31 (1.12–1.56) .001
SLE= systemic lupus erythematosus, RA= rheumatoid arthritis.
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cohort. An alpha value less than or equal to 0.05 was considered
significant in all analysis.
A post-hoc power analysis was performed to test for the
likelihood of type 2 errors, in which true correlations are missed
due to inadequate sample size. The advantage of a post-hoc
power analysis is that it can consider the actual variation seen in
the sample, as opposed to a projected variance, and thus provides
a realistic analysis. The power analysis revealed a very low
probability (nothing less than 0.84) for this type of error in all of
the correlation analyses, which were the basis for all of the
conclusions drawn in this study (Table 4).
3. Results
The study was comprised of 77 Caucasian men and women with
a mean age of 48.38±12.17 years. The sociodemographic
information gathered about each cohort is displayed in Table 1.
Of the 77 subjects, 15 were diagnosed systemic lupus
erythematosus patients, 21 were diagnosed rheumatoid arthritis
patients, 20 subjects were healthy controls, and 21 were
individuals being treated for depression at a private psychiatric
clinic. The lupus patients had an average age of 49±8.21 years.
The arthritis patients had an average age of 52.71±11.17 years,
while the healthy controls and depressed subjects had a mean of
43.95±11.77 and 47.81±14.8 years, respectively. There is some
variability between the mean ages of the groups, but this
difference was not found to be statistically significant (Table 1).
The level of education receivedbasedonyears in school is similar
for the SLE, depressed, and RA subjects. However, the healthy
control group had a higher percentage of well-educated members
(P< .001). The distribution of marital status was similar for all the
study groups with the majority of subjects currently in a marital
relationship. There were some slight differences in employment
status between the groups. The distribution between the SLE and
RA patients is similar, with 33% of patients from both groups
currently employed, while the healthy control and depressed
groups had 70% and 62% of the study subjects currently
employed, respectively. The differences between the employment
status of the study cohorts were not considered significantly
different (Table 1). Although the difference did not reach statistical
significance, the finding that only half as many patients with either
lupus or rheumatoid arthritis were employed is suggestive of the
degree of disability that accompanies these diseases.
3.1. Clinical manifestations
The SLE cohort had ameandisease duration of 17.80±7.32 years,
which was similar to the mean duration of disease among the
rheumatoid arthritis subjects, 17.57±10.24 (Table 5). The mean
body mass index scores were fairly similar for all groups. It is
important to note that the potential confounding variables of
smoking, drinking, and physical activity are similar between the
groups being compared in the study (Table 5). The SLE patients
demonstrated higher pain scores on average than all of the other
groups, and significantly higher than the healthy control group
(P< .001). Univariate regression analysis found that none of these
characteristics showeddirect correlationwithdepression (Table2).
The SLE patients did not have elevated levels of sedimentation
velocity (mm/h), leukocyte concentrations (109/L), or lymphocyte
percentage. These measurements were similar between the SLE
and RA subjects (Table 5). However, RA patients had elevated
levels of CRP compared with the SLE patients (P= .010). This has
been previously observed when comparing SLE and RA
laboratory data.[34] The SLE patients exhibited increased levels
of both IL-6 and IL-10 compared with the healthy subjects
(P= .038 and P= .016, respectively) (Fig. 1).While there are some
slight differences between the levels of IL-6, IL-10, and TNF-a
between the other groups, these differences are not significantly
different. Univariate regression analysis demonstrated an inverse
correlation between IL-10 levels and depression in the SLE
subjects (P= .036) (Table 2) (Fig. 2).
3.2. Psychosocial function
The SLE subjects had the highest proportion of individuals with
moderate to severe depression of any group. Forty percent of the
Table 4
Post hoc power analysis of study cohorts.
Characteristics
Linear regression T test
SLE Healthy Depressed RA SLE Healthy Depressed RA
Age N/A N/A N/A N/A 1.000 1.000 0.999 1.000
Education, y N/A N/A N/A N/A 0.670 1.000 0.975 0.351
Disease Duration 0.930 N/A N/A 0.886 0.966 N/A N/A 0.619
BMI 0.932 N/A 0.970 0.884 0.999 1.000 1.000 1.000
Pain 0.932 N/A 0.974 0.897 0.676 0.668 0.928 0.885
SV 0.890 N/A N/A 0.896 0.030 N/A N/A 0.069
CRP 0.891 N/A N/A 0.891 0.069 N/A N/A 0.090
Leukocytes 0.889 N/A N/A 0.884 0.999 N/A N/A 0.596
Lymphocytes 0.890 N/A N/A 0.894 1.000 N/A N/A 0.999
Anti-dsDNA Ig 0.888 N/A N/A 0.884 N/A N/A N/A N/A
IL-6 0.911 N/A 0.971 0.593 0.045 0.076 0.258 0.081
IL-10 0.894 N/A 0.972 0.616 0.393 0.083 0.257 0.232
TNF 0.891 N/A 0.970 0.595 0.151 0.201 0.295 0.139
HADS Depression N/A N/A N/A N/A 0.610 0.135 0.400 0.058
HADS Anxiety N/A N/A N/A N/A 0.941 0.922 0.971 0.297
Pittsburgh Sleep Quality Index 0.889 N/A 0.971 0.884 0.978 0.911 0.996 0.206
Relationship Assessment Scale 0.845 N/A 0.445 0.682 1.000 1.000 1.000 1.000
Fatigue Severity Scale 0.903 N/A 0.967 0.872 0.999 0.981 0.865 0.999
Multivariate Model=0.655
Figueiredo-Braga et al. Medicine (2018) 97:28 www.md-journal.com
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SLE patients demonstrated HADS depression scores above 10
(Table 5). The SLE patients showed a 6-fold greater likelihood
than the healthy control group to have moderate or severe
depression (P= .007, Mann–Whitney U test, Table 5). The SLE
patients had significantly higher depression scores than the
healthy control subjects (P= .007), but not higher than the
depressed or RA subjects. The SLE subjects experienced higher
levels of anxiety compared to both the healthy controls and the
RA patients (P= .020 and P= .011, respectively). However, the
depressed group had similar anxiety scores.
Upon examination of the quality of sleep that the study patients
were experiencing, as recorded by the Pittsburgh Sleep Quality
Index (PSQI) assessment, the SLE cohort had a mean index of
7.67±3.06, which was higher than the healthy control subjects
(P= .005). A higher PSQI indicates a lower quality of sleep, while
a higher quality of sleep is indicated by lower scores. The SLE
cohort had 67% report poor sleep quality based on the PSQI
Figure 1. Cytokine serum concentrations differ between cohort subgroups.
SLE IL-6 and IL-10 serum concentrations are statistically higher than healthy
subjects. RA patients demonstrate slightly higher average serum levels of pro-
inflammatory cytokines IL-6 and TNF-a. Depressed and SLE patients
demonstrate slightly higher concentrations of IL-10 on average than other
cohort subjects. IL = interleukin, RA = rheumatoid arthritis, SLE = systemic
lupus erythematosus, TNF = tumor necrosis factor.
Figure 2. Linear regression identifies clinical and psychological assessments
that are correlated with depression in SLE patients. Univariate analysis found
IL-10, relationship assessment scale, and fatigue severity scale values to be
correlated with depression in our SLE cohort. IL-10 and relationship
satisfaction are negatively correlated with depression, while fatigue severity
is positively correlated.
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standard. This distribution of patients who experienced lower
quality of sleep is similar in the SLE cohort compared with the
depressed and RA subjects (Table 5).
All married and cohabitating cohort patients had their
relationship satisfaction measured based on the relationship
assessment scale criteria. Higher values indicate increased
satisfaction with their significant other or spouse. Interestingly,
the SLE patients record less satisfaction in their relationship than
any of the other subgroups, with a mean scale score of 24.75±
4.81. This score was significantly lower than both the healthy
control and RA patients (P= .050 and P= .015, respectively). The
decrease in relationship satisfaction for SLE patients compared to
primary depression patients did not reach statistical significance.
The RA patients, albeit also suffering from a chronic and
debilitating autoimmune disease, had a mean relationship
assessment scale score of 30.82±5.69. The reported scores for
SLE patients from the relationship assessment scale showed a
distinct negative correlation with HADS depression scores
(P= .007) (Table 2) (Fig. 2).
To measure the combination of both physical and mental
fatigue that the patients were experiencing, the fatigue severity
scale was utilized. Higher scores indicate higher fatigue reported
by the patient. The SLE patients reported a mean score of 4.6±
1.30, which was similar to the RA patients who reported a fatigue
score of 4.93±1.62 (Table 5). This was significantly more than
the healthy control subjects (P= .002). Of interest is the fact that
the depressed patients did not have significantly lower fatigue
than the SLE subjects (P= .234) While depressed patients do not
have fatigue scores that were as elevated as fatigue scores in
patients with SLE, patients who are depressed on average report
higher scores than those observed in “healthy” populations. This
finding is unsurprising as individuals with depression commonly
report fatigue as a common symptoms, and is often observed by
physicians who treat depressed patients.[35] The SLE patients
were nearly 4.57 times more likely to have heightened levels of
fatigue compared to the healthy control patients. Further, a direct
positive correlation was observed between fatigue severity scale
scores and depression levels in the SLE patients (P= .001)
(Table 2).
3.3. Multivariate analysis
Of the data collected from the clinical and psychosocial
assessment of the SLE patients, we investigated which character-
istics that correlated with depression could best indicate
depression in our model.[35–37] Due to the relatively small SLE
cohort of this study, the model could not compensate for age or
socioeconomic status as would be appropriate for a larger cohort.
However, it can still indicate which variables among those
identified in the study show the closest correlation with
depression among the patients. Anxiety was not included as a
candidate for the multivariate model due to the co-relatedness
with the HADS depression score and because it was derived from
the same assessment as the depression score. Both the fatigue
severity (P= .028) and relationship assessment (P= .042) scales
were indicated as strong correlates and predictors of depression
among the SLE cohort (Table 6).
4. Discussion
The study utilized the comparison of multiple groups to identify
the factors that influence depression in patients with systemic
lupus erythematosus. Comparing the RA and SLE patients shows
what is likely the result of a chronic inflammatory disease.
Comparison with the depression group indicates what factors are
the result of psychological components. Taken together, the use
of these groups offers a new perspective on factors that could be
relevant to depression in the SLE patients. The strongest findings
were that: first, levels of IL-10 show a correlation with HADS
depression scores and appear to be a good indicator of depression
in SLE patients. Second, relationship assessment scale scores were
lower on average among our SLE patients compared with all
other patient cohorts, and relationship assessment scale scores
showed a correlation with HADS depression scores, implying
that relationship assessment would be another indicator of
depression for SLE patients. Lastly, the fatigue severity scale
scores were strongly correlated with HADS depression scores in
SLE patients in both univariate and multivariate analysis. This
instrument was the most sensitive in relation to correlation with
HADS depression scores, as evidenced by the heightened odds
ratios, and appears to be a good predictor of depression in SLE
patients.
The SLE cohort had increased pain levels compared to the
healthy control cohort, but not to either the depressed or arthritis
patients. Pain and depression are strongly interwoven in physical
and psychiatric disorders[38] and SLE.[39]
Previous studies have shown that IL-6 and IL-10 can be
associated with depression.[40] Several cross-sectional studies
have found that those exhibiting depressive manifestations have
increased levels of CRP, TNF-a, IL-1, IL-6, and IL-2 and that
these are associated with depression in patients being treated for
clinical depression.[41,42] We also observed that IL-6, IL-10, pain
scores, Pittsburgh sleep quality index scores, relationship
assessment scale scores, and fatigue severity scale scores were
correlated with increased HADS depression scores in depressed
patients (Table 2). We also observed elevated levels of IL-6 in the
SLE cohort compared to the healthy patients. Increased levels of
IL-6 in SLE and RA patients agree with the current literature, as
patients being treated for depression often exhibit elevated levels
of IL-6.[41,43,44] IL-6 could be a good indicator of depression in
general; however, we did not find that IL-6 levels were
significantly correlated with HADS depression scores among
our SLE cohort. Since lupus patients have increased levels of IL-6
overall, this may mask an association between IL-6 and
depression in lupus. It is likely that this is why we do not
observe a correlation between our SLE cohort’s IL-6 levels and
HADS depression scores.
The SLE cohort displayed increased serum concentrations of
IL-10 compared to the healthy control subjects. However, the IL-
10 levels measured from our SLE patients were actually lower on
average than those measured from our depressed subjects. The
difference in IL-10 concentrations between these 2 groups was
not significant.
IL-10 is responsible for helping drive the Th2 mediated
response that results in increased B cell activation, IgG class
switching, and increased antibody production. It is also strongly
Table 6
Multivariant model for SLE Study Cohort 2.
Variables Odds ratio (95% CI) P value
Fatigue Severity Scale 1.21 (1.03–1.45) .028
Relationship Assessment Scale 0.95 (0.91–1.00) .042
Model Fit Summary pseudo R2 AICc
0.952 67.400
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associated with disease activity in patients with SLE.[45–47]
Relatively lower levels of IL-10 were associated with more severe
HADS depression scores in the lupus patients, a finding that was
unexpected, especially since there was an association between
higher IL-10 and more severe depression in the RA and depressed
patients (Table 2). This type of relationship between IL-10 and
depression is unexpected, as it may be expected that increased
disease activity would cause increased IL-10 and depression, not
the opposite. The negative trend between IL-10 and HADS
depression scores in our SLE cohort could be due to the different
pathophysiology of SLE when compared with other rheumato-
logical and immunological diseases such as RA. Given that it
contradicts other published studies, it is also possible that in this
case it is a false positive result. However, these findings call for
further investigation into the role of IL-10 in depression,
especially depression in lupus.
It is still unclear if IL-10 is related to depression as there are
conflicting reports in the literature with regard to human
studies[48] and in animal models.[49] IL-10 imbalance does affect
depressive behaviors.[50] In studies involving SLE patients it has
been previously observed that heightened levels of IL-10 are likely
correlated with depression and neuropsychiatric disorders.[51,52].
Investigation into a relationship between lupus disease activity
and depression or anxiety has met with mixed results, with some
studies indicating a correlation and others not finding evidence
for correlation.[5–9] Although some studies have indicated that
disease activity correlates with depression, there may be
confounding factors that mask the effects. These could include
such things as depressive symptoms lagging behind inflammatory
indicators, socioeconomic factors masking or exacerbating
depression, or personal psychological variables such as cognition,
helplessness, or resilience that interfere with a straightforward
analysis.
The SLE patients presented elevated anxiety scores, signifi-
cantly more than the healthy and RA subjects. This supports
observations of other studies.[53,54] Anxiety scores, although still
higher in the lupus patients, were not significantly different from
the depressed patients. The increased anxiety scores of the SLE
patients compared to the RA patients suggest that increased levels
of anxiety in lupus are not likely to be due only to the pain,
disability, or fear that comes from the presence of a chronic
inflammatory disease, as these are also present in rheumatoid
arthritis. These factors likely still contribute to anxiety, but
cannot completely explain the heightened anxiety in lupus
patients.
Unique to this study was the correlation observed between
relationship assessment scale (RAS) and HADS depression
scores. The SLE patients have the lowest average RAS score
between all the subgroups in the study, significantly lower than
the healthy and arthritis patients. In addition, the RAS scores
reported from the SLE patients were significantly correlated to
depression in the univariate and multivariate analysis (Tables 2
and 6). While a large quantity of studies have observed that
quality of life is negatively affected in SLE patients and is
correlated with depression, none have utilized the relationship
assessment scale to quantify relationship satisfaction. Relation-
ship quality and adjustment is known to contribute to better or
worse coping with illness, and bidirectionally influences depres-
sion.[55]
This study provides evidence that depression and relationship
satisfaction show a correlation in the SLE patients. The finding
that the RA patients have higher relationship satisfaction than
lupus patients despite also having chronic autoimmune disease
indicates that it is likely that specific biological or psychological
manifestations of lupus affect the relationship in addition to the
physical limitations of a chronic disease.
Many studies have noted the importance of social support, both
familial and nonfamilial,with regards to depression.[56–60]Wealso
observed a correlation between depression scores and relationship
satisfaction in our depressed patient cohort (Table 2). Social
support is a crucial environmental resource that is necessary for
mental health. Good social support has been shown to provide
protection from depression and elevate individual’s emotional
state.[61] It has also been established that depressive characteristics
are associated with a decrease in peer-related social support.[56,62]
While the data generated from our cohort study does not allow us
to determine directionality of the relationship between relationship
satisfaction and depression, it is clear that familial social support is
important for mental health and that a decrease in relationship
satisfaction is an indicator of depression.
In this study we found the SLE cohort to have higher PSQI
values, indicating poor sleep compared to the healthy control
group, but these values were not significantly different from the
arthritic and depressed patients. These results suggest that the
sleep quality of SLE patients, while not good, does not likely
contribute directly to depression. For the time being, treatment of
fatigue remains an obstacle for patients and health care
professionals to surmount. Given that the depression in lupus
is significantly related to fatigue (Table 6), it may be that the
treatment of depression can lead to improvements in fatigue.
While this study provides some valuable insight into the factors
associated with depression in patients suffering from systemic
lupus erythematosus, it does exhibit several distinct limitations.
First, the samples sizes of the SLE, RA, Healthy, and primary
depression cohorts are all relatively small, with the patient
cohorts not exceeding more than 21 at the most and the SLE
patient cohort containing only 15 subjects. Another limitation to
consider is the sociodemographic imbalance of the SLE cohort to
the healthy subjects. While the SLE, RA, and depressed subjects
tend to share similar sociodemographics, the healthy subjects
tend to have more education and demonstrate lower levels of
unemployment. This could be a confounding factor in depres-
sion. It likely also indicates the level to which lupus causes
disability and interferes with productivity.
Depression and anxiety in lupus are influenced by a
complicated mix of biological, social, and psychological factors.
This study found that fatigue severity, relationship satisfaction,
and IL-10 concentrations are indicators of depression in lupus
patients, with fatigue and relationship satisfaction being the best
predictors of depression. Interestingly, these 3 variables represent
all 3 of the different influences: biological, social, and
psychological. Continued study of these factors is necessary to
fully understand the causes and potential treatments for these
debilitating aspects of lupus.
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